Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a fully integrated, commercial-stage biopharmaceutical company, announced that management will present and host one-on-one meetings at Guggenheim's 3rd Annual Healthcare Innovation Conference in Boston on Nov. 10, 2026. President and CEO Seth Lederman, M.D., will deliver the company presentation from 4 to 4:25 p.m. ET. A live webcast and replay will be available under the News & Events tab in the Investors section of the company's website.
The presentation is significant for investors and the healthcare industry because Tonix has recently achieved a major milestone with the approval of TONMYA(TM) (cyclobenzaprine HCl sublingual tablets 2.8mg), the first new treatment for fibromyalgia in more than 15 years. As a fully integrated, commercial-stage company, Tonix's participation at a prominent healthcare innovation conference provides an opportunity to highlight its commercial infrastructure and pipeline to a targeted audience of investors and industry experts.
Tonix Pharmaceuticals is focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. Its CNS commercial infrastructure supports marketed products, including its acute migraine products, Zembrace(R) SymTouch(R) and Tosymra(R). The company is also maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. Additionally, Tonix's CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. The company is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
For those unable to attend, the live webcast and replay will be accessible on the company's website, ensuring broad access to the presentation. Investors and industry watchers can view the full press release at https://ibn.fm/f7udM. The latest news and updates relating to TNXP are available in the company's newsroom at https://ibn.fm/TNXP.
The announcement was distributed through InvestorWire, a specialized communications platform with a focus on advanced wire-grade press release syndication. InvestorWire is part of the Dynamic Brand Portfolio at IBN, which provides access to a vast network of wire solutions, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions.
This news matters because it underscores Tonix's commitment to advancing treatments for CNS and immunology conditions while engaging with the investment community. The company's presentation at a leading healthcare innovation conference could enhance its visibility and attract potential investors, especially following the recent approval of TONMYA for fibromyalgia. As Tonix continues to develop its pipeline, including investigational candidates like TNX-2900, TNX-4800, and TNX-1500, the conference provides a platform to communicate its progress and strategic vision. However, it is important to note that Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.
